Guardian Pharmacy Services (NYSE:GRDN) versus VYNE Therapeutics (NASDAQ:VYNE) Head-To-Head Analysis

Guardian Pharmacy Services (NYSE:GRDN) and VYNE Therapeutics (NASDAQ:VYNE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Institutional and Insider Ownership

83.8% of VYNE Therapeutics shares are held by institutional investors. 33.0% of Guardian Pharmacy Services shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Guardian Pharmacy Services has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500.

Profitability

This table compares Guardian Pharmacy Services and VYNE Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guardian Pharmacy Services	3.64%	30.72%	15.99%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Earnings & Valuation

This table compares Guardian Pharmacy Services and VYNE Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardian Pharmacy Services	$1.45 billion	1.40	$49.22 million	$0.83	49.17
VYNE Therapeutics	$570,000.00	33.29	-$26.48 million	($0.38)	-74.54

Guardian Pharmacy Services has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Guardian Pharmacy Services and VYNE Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardian Pharmacy Services	0	2	7	0	2.78
VYNE Therapeutics	1	3	0	0	1.75

Guardian Pharmacy Services presently has a consensus price target of $42.83, suggesting a potential upside of 4.96%. Given Guardian Pharmacy Services’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Guardian Pharmacy Services is more favorable than VYNE Therapeutics.

Summary

Guardian Pharmacy Services beats VYNE Therapeutics on 11 of the 14 factors compared between the two stocks.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.